© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Conference Articles
Genomic Testing Impacts Treatment Decisions in Prostate Cancer
June 29th 2020, 4:30pm
Eric A. Klein, MD, discusses the role of genomic testing in patients with prostate cancer and how these findings can impact treatment decisions.
Darolutamide OS Stands Up to Other Approved Drugs for the nmCRPC
June 28th 2020, 12:00pm
In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.
Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS
June 2nd 2020, 8:00pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Discussing How to Bring Next-Generation Sequencing to Community Practices
June 1st 2020, 8:00pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.
Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review
June 1st 2020, 12:00am
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
"The ARROW trial results presented today during the ASCO virtual meeting showed that patients with RET fusion–positive lung cancer treated with the selective RET inhibitor pralsetinib had durable responses. In addition to supporting the development of pralsetinib across a broad population, these data highlight the urgency to test [patients with] lung cancer with next-generation sequencing so that eligible patients may be identified for treatment."
Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
May 31st 2020, 8:30pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
Patients with ALK-positive non–small cell lung cancer showed clinically meaningful improvement in overall survival when receiving alectinib, a highly selective second-generation TKI, versus those treated with crizotinib, according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.
Investigation of Tepotinib Shows Durable Benefit in NSCLC With a METex14 Skipping Mutation
May 31st 2020, 8:15pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer and a MET exon 14 skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial presented during the at the 2020 Virtual Scientific Meeting and published in the New England Journal of Medicine.
Clinically Meaningful Activity Observed With Combination Cabozantinib and Atezolizumab in mCRPC
May 31st 2020, 7:30pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.
Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
May 31st 2020, 7:15pm
Targeted Oncology's Coverage of the ASCO Virtual Scientific Program
Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.